After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of BridgeBio Pharma Inc is $5.35B. A total of 1.47 million shares were traded on the day, compared to an average of 1.86M shares.
In the most recent transaction, Scott Randal W. sold 2,500 shares of BBIO for 34.00 per share on Mar 01 ’24. After the transaction, the Director now owns 6,500 company shares. In a previous transaction on Feb 15 ’24, Valantine Hannah sold 2,915 shares at 37.75 per share. BBIO shares that Director owns now total 1,764.
Among the insiders who sold shares, Valantine Hannah disposed of 2,915 shares on Jan 16 ’24 at a per-share price of $37.97. This resulted in the Director holding 1,764 shares of BBIO after the transaction. In another insider transaction, MCCORMICK FRANK sold 100,000 shares at $42.06 per share on Dec 26 ’23. Company shares held by the Director now total 627,689.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, BBIO has a high of $44.32 and a low of $11.75.
As of this writing, BBIO has an earnings estimate of -$0.92 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.74 per share and a lower estimate of -$1.18. The company reported an EPS of -$1.08 in the last quarter, which was -31.70% lower than expectations of -$0.82.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$7.73, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.82.
